Experience of successful use of immunotherapy in treatment of locally advanced inoperable squamous cell carcinoma of the hairy part of the head

Cover Page

Cite item

Full Text

Abstract

This article presents the experience of successful use of immunotherapy in treatment of locally advanced inoperable squamous cell carcinoma of the hairy part of the head.

About the authors

B. G. Pkheshkhova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; Рeoples’ Friendship University of Russia (RUDN University)

Author for correspondence.
Email: belapkheshkhova@mail.ru
ORCID iD: 0000-0003-1448-1733

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

6 Miklukho-Maklaya St., Moscow 117198

Russian Federation

A. M. Mudunov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0002-0918-3857

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

M. B. Pak

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-4546-0011

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

P. A. Zeynalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-1564-424X

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

A. F. Batsev

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-1794-7247

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

References

  1. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).
  2. Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166(5):1069–80. doi: 10.1111/j.1365-2133.2012.10830.x
  3. Brougham N.D., Dennett E.R., Cameron R., Tan S.T. The incidence of metastasis form cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012;106(7):811–5. doi: 10.1002/jso.23155
  4. Benjamin C.L., Ananthaswamy H.N. p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol 2007;224(3):241–8. doi: 10.1016/j.taap.2006.12.006
  5. Liu Q., Yu S., Zhao W. et al. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer 2018;17(1):53. doi: 10.1186/s12943-018-0793-1
  6. Hung K.F., Sidorova J.M., Nghiem P., Kawasumi M. The 6–4 photoproduct is the trigger of UV-induced replication blockage and ATR activation. Proc Natl Acad Sci U S A 2020;117(23):12806–16. doi: 10.1073/pnas.1917196117
  7. Pickering C.R., Zhou J.H., Lee J.J. et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 2014;20(24):6582–92. doi: 10.1158/1078-0432.CCR-14-1768
  8. Potenza C., Bernardini N., Balduzzi V. et al. A review of the literature of surgical and nonsurgical treatments of invasive squamous cells carcinoma. Biomed Res Int 2018;2018:9489163. doi: 10.1155/2018/9489163
  9. Sapijaszko M., Zloty D., Bourcier M. et al. Non-melanoma skin cancer in Canada. Chapter 5: Management of squamous cell carcinoma. J Cutan Med Surg 2015;19(3):249–59. doi: 10.1177/1203475415582318
  10. Veness M.J., Morgan G.J., Palme C.E., Gebski V. Surgery and adjuvant radiоtherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005;115(5):870–5. doi: 10.1097/01.MLG.0000158349.64337.ED
  11. Karia P.S., Morgan F.C., Ruiz E.S., Schmults C.D. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma: a systematic review and Pooled Analysis of Outcomes Data. JAMA Dermatol 2017;153(8):781–8. doi: 10.1001/jamadermatol.2017.1680
  12. Cognetta A.B., Howard B.M., Heaton H.P. et al. Superficial x-ray in the treatment of basal and squamous cell carcinomas: A viable option in select patients. J Am Acad Dermatol 2012;67(6):1235–41. doi: 10.1016/j.jaad.2012.06.001
  13. Schmults C.D., Blitzblau R., Aasi S.Z. et al. NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022. J Natl Compr Canc Netw 2021;19(12):1382–94. doi: 10.6004/jnccn.2021.0059
  14. Peyrade F., Kogay M., Viotti J. et al. Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective: a real-life analysis. Ann Oncol 2018;29(Suppl 8):viii442–viii466. doi: 10.1093/ANNONC/MDY289.049
  15. Foote M.C., McGrath M., Guminski A. et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 2014;25(10):2047–52. doi: 10.1093/annonc/mdu368
  16. Maubec E., Boubaya M., Petrow P. et al. Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN. J Clin Oncol 2019;37(15 Suppl):9547. doi: 10.1200/JCO.2019.37.15_suppl.9547
  17. Blum V., Müller B., Hofer S. et al. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. Eur J Dermatol 2018;28(1):78–81. doi: 10.1684/ejd.2017.3209
  18. Borradori L., Sutton B., Shayesteh P., Daniels G.A. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol 2016;175(6):1382–6. doi: 10.1111/bjd.14642

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.